Janssen publicizes more Darzalex data

Genmab’s US partner Janssen has presented new data on the effect of the cancer drug Darzalex.

Photo: Tuala Hjarnø / Genmab / PR

On Friday, Genmab’s partner released more data from the phase III MAIA study with Darzalex (daratumumab). This data should not have a major effect on the Genmab share price. 

"From an interest rate perspective, you shouldn’t put too much into it. However, this says something about the effect and responses connected with Darzalex," states Sydbank Chief Equity Analyst Søren Løntoft Hansen. 

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs